Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old

Press/Media

Period	11 Oct 2022

Media coverage

Title	Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old
Media name/outlet	Hugin - English
Country/Territory	United States
Date	11/10/22
URL	metabase.moreover.com/noarticleurl?type=psh&lni=66KH-MDS1-JDPT-Y0J4-00000-00
Persons	Mirna Chehade